Search

Your search keyword '"Opalka, Bertram"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Opalka, Bertram" Remove constraint Author: "Opalka, Bertram" Database Unpaywall Remove constraint Database: Unpaywall
81 results on '"Opalka, Bertram"'

Search Results

1. Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

3. Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition

4. GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia

6. Dexamethasone‐mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells

8. AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

10. Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales

11. Expansion of functional personalized cells with specific transgene combinations

12. Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome

13. the Role of MSCs in the Development of Acute Myeloid Leukemia

15. GFI1b As a Novel Oncosuppressor in AML

16. GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome

20. Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia

22. Gfi1b-A Novel Tumor Suppressor In Acute Myeloid Leukemia

23. Complementation of non-tumorigenicity of HPV18-positive cervical carcinoma cells involves differential mRNA expression of cellular genes including potential tumor suppressor genes on chromosome 11q13

25. Pluripotent stem cells escape from senescence-associated DNA methylation changes

26. Telomeres and prognosis in patients with chronic lymphocytic leukaemia

32. Gene Therapy of βc-Deficient Pulmonary Alveolar Proteinosis (βc-PAP): Studies in a Murine in vivo Model

39. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections

40. Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple Myeloma

41. Therapy-Associated Immunosuppression and Opportunistic Infections in Multiple Myeloma Patients.

43. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival

45. Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer

46. In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment

47. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector

48. Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system

Catalog

Books, media, physical & digital resources